Vaccines are very effective and they cut down the risk of having Covid 19. It helps you from the virus and spreading the virus.
The research of 23 million people found that vaccine protects us from Covid 19 at least 90%.
Those who are in the age group of 50 to 75 will be protected from Covid for at least five months, founded in the study.
The vaccine prevents Covid 19 by at least 90% in the age group of 50 and older, a real-world survey of the estimated 23 million people has found.
The survey was organized by the french government-backed scientific organization Epi-Phare, in that survey, they found that after five months of vaccination the people of the age group over 75 were less likely to be hospitalized in comparison to unvaccinated people in the same age group.
“The reduction in risk for those aged 50 to 74 was even higher, at 97%, the study authors said in a press release published Monday.
“This means that those who are vaccinated are nine times less at risk of being hospitalized or dying from COVID-19 than those who have not been vaccinated,” the epidemiologist Mahmoud Zureik, who oversaw the research, told Agence France-Presse, per The Guardian
The research, that used the information from the French National Health Data System, is huge itself, containing a total number of 22.6 million people – 7.2 million over 75 years old and 15.4 million people aged 50 to 74.
The real-world research from UK, US, and Israel found that Covid 19 vaccine protection lasted five months in old people.
Zureik told Agence France-Presse that ignoring the most dangerous infections was “the main public health objective.”
An epidemic without serious infections is no longer an epidemic,” he said.
Read More: Wasted COVID immunization dosages in Louisiana swell to 224,000
So many people, 85.3%, in the age group of over 75 had been vaccinated from Pfizer‘s COVID-19 shot. A small group of people is vaccinated from Moderna shots and AstaZeneca’s shots, at 8.7% and 6.1% respectively.
53.6% of the younger people are vaccinated from Pfizer’s vaccine, 39.2% AstraZeneca’s, and 7.1% Moderna’s.
The cut-off for the review was July 20, which implies it just incorporates a month of information for the profoundly irresistible Delta variation, which became predominant in France in June.
Zureik let Agence France-Presse know that this was”a very short period to evaluate the real impact of the vaccination on this variant,” adding that the exploration was continuous.
Read More: Merck Requests That FDA Approve The Main Pill To Treat COVID-19